Could a psoriasis drug help save Insulin-Making cells in type 1 diabetes?

NCT ID NCT04589325

Ongoing Disease control Sponsor: Göteborg University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether ixekizumab (Taltz), a drug already approved for psoriasis, can help people newly diagnosed with type 1 diabetes keep making their own insulin. The study involves 127 adults aged 18-45 who were diagnosed within the last 100 days. Participants receive either the drug or a placebo for 12 months, and researchers measure how much insulin their bodies still produce after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ixekizumab (Taltz)
What this could lead to: If it works, this could point toward a treatment that helps people with new-onset type 1 diabetes keep making their own insulin longer.
What could go wrong: This is an early phase 2 trial with only 127 participants, so results may not apply to everyone. The drug also has known risks like infections and allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE1 DIABETES MELLITUS

Contacts and locations

Locations

Centrum för Diabetes,

Stockholm, Sweden
Falu Lasarett

Falun, Sweden
Karlstad lasarett

Karlstad, Sweden
Kristianstad Hospital

Kristianstad, Sweden
Linköping University Hospital

Linköping, Sweden
Lund University Hospital

Lund, Sweden
Länssjukhuset Ryhov

Jönköping, Sweden
NU-Hospital Group

Uddevalla, Sweden
Sahlgrenska University Hospital, Sahlgrenska

Gothenburg, Sweden
Sahlgrenska University Hospital, Östra Hospital

Gothenburg, Sweden
Skaraborgs sjukhus

Skövde, Sweden
Södersjukhuset Hospital

Stockholm, Sweden
Södra Älvsborg Hospital

Borås, Sweden
Uppsala Academic Hospital

Uppsala, Sweden
Varbergs sjukhus

Varberg, Sweden
Vrinnevi Hospital

Norrköping, Sweden
Örebro University Hospital

Örebro, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.